United States connected drug
delivery devices market is expected to register an impressive CAGR in the
forecast years. The market showed a consistent growth in the historical years
from 2018-2022, on account of increase in awareness among consumers regarding
the use of self-administrated and connected drug therapy. Rise in cost for
in-patient stay at healthcare facilities along with high demand for advanced
drug delivery solutions is expected to fuel the market demand. Improvement in
quality of patient care and compliance and the changing healthcare
infrastructure are expected to boost the United States connected drug delivery devices
market growth.
Connected sensors
have convenient integration with the existing delivery devices and thus they
dominate the market. The segment is anticipated to dominate the United States
connected drug delivery devices market in next five years. Connected sensors do
not interfere with working of delivery devices and are reusable even if the
delivery device is disposed. Moreover, increasing cases of chronic respiratory
diseases, chronic obtrusive pulmonary disease are expected to boost the demand
for integrated connected drug delivery devices in the future. The smart
wireless electronic systems developed for the delivery of desired drug commonly
known as connected drug delivery devices results in patient monitoring and
counselling the patients with conditions such as asthma, diabetes, hepatitis C,
hypertension, tuberculosis, Chronic Obstructive Pulmonary Diseases (COPD), etc.
Additionally, the rise in
initiatives and campaigns by healthcare facilities and top authorities to
promote the benefits of taking prescribed drugs at the right time and on time
to ensure that patients receive effective treatment is anticipated to support
the growth of the connected drug delivery devices market. Also, the awareness
regarding the benefits of connected system over the traditional drug delivery
system with improved patient response is expected to accelerate the growth of
the United States connected drug delivery devices market.
Rise in Prevalence
of Chronic Diseases
Connected drug delivery
systems support the doctors to keep the track of their patients in determining
the effectiveness of prescribed treatments and to adjust the patient's care as
required. For instance, for people with chronic diseases such as diabetes
and asthma, connected drug delivery devices can be helpful for self-medication
management. According to Asthma and Allergy Foundation of America, in United
States, about 20 million adults below and above age of 18 years have asthma
in which around 9.8% of female adults have asthma, compared to 6.1% of male
adults. These factors are anticipated to boost the growth of United States
connected drug delivery devices market in the forecast years.
Increasing R&D
Activities
Rapid advancements in research and
development (R&D) for developing drug delivering devices for the treatment
of infectious/chronic diseases are contributing to the market growth. For instance, according to several researchers, the United States spent USD607.5
billion in R&D activities, with USD101.1 billion (17%) of annual R&D
spending classified as basic research. Additionally, a pharmaceutical company namely Eli Lily in 2021,did the
cooperation of four distinct businesses—Gloko Inc., DexCom Inc., Roche, and my
Diabby Healthcare—works to promote connected solutions for diabetics in
international markets, driving the growth of the United States connected drug
delivery devices market. .
Growing Awareness Amongst Patient to Boost
Medication
Connected drug delivery devices offer the right dosage
and administration for the successful treatment without any cost-efficient
interventions. According to
Clinicaltrials.gov, 13 clinical trials took place for the development of
connected drug delivery devices. Due to the awareness amongst people, more
and more patients are adopting these delivery devices to support the treatment
more efficiently, thus helping to reduce the number of visits to clinics and
hospitals and reduce the patient’s efforts to comply with prescribed
medication. Additionally, it reduces the wastage of costly medications such as
injectable biologics and is expected to fuel the growth of the United States
connected drug delivery devices market.
Download Free Sample Report
Market Segmentation
The United States
connected drug delivery devices market is segmented by product type, technology,
application, end user, company and regional distribution. Based on product
type, the market is further fragmented into connected sensors, and integrated
connected devices. Based on technology, the market is further fragmented into bluetooth,
near field communication, and others. Based on application, the market is
further fragmented into asthma & COPD, diabetes, and others. Based on end
user, the market is segmented into healthcare providers
and homecare.
Company Profiles
Abbott
Laboratories, Inc., F. Hoffmann-La Roche Ltd. (USA), Reciprocal Labs Corporation (Propeller
Health), Teva USA, Merck & Co., West
Pharmaceutical Services, Inc., Molex LLC (Phillips Medisize), Cohero Health,
Inc., Becton, Dickinson, and Company, Unilife Corporation etc. are some of the key players
operating in the United States Connected Drug Delivery Devices Market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historical Years
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report Coverage
|
Revenue forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments Covered
|
Product Type
Technology
Application
End User
|
|
Region Covered
|
North-East, Mid-West,
South, West
|
|
Key Companies Profiled
|
Abbott Laboratories, Inc., F. Hoffmann-La Roche Ltd. (USA), Reciprocal
Labs Corporation (Propeller Health), Teva USA, Merck & Co., West
Pharmaceutical Services, Inc., Molex LLC (Phillips Medisize), Cohero Health,
Inc., Becton, Dickinson, and Company, Unilife Corporation.
|
|
Customization Scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase
options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, United
States connected drug delivery devices market has been segmented into
following categories, in addition to the industry trends which have also been
detailed below:
- United States Connected Drug Delivery Devices Market, By Product
Type:
- Connected Sensors
- Integrated Connected
Devices
- United States Connected Drug Delivery Devices Market, By Technology:
- Bluetooth
- Near Field Communication
- Others
- United
States Connected Drug Delivery Devices Market, By Application:
o
Asthma & COPD
o
Diabetes
o
Others
- United
States Connected Drug Delivery Devices Market, By End User:
o
Healthcare Providers
o
Homecare
- United
States Connected Drug Delivery Devices Market, By Region:
- North-East
- Mid-West
- South
- West
Competitive
Landscape
Company Profiles: Detailed analysis of the major
companies present in the United States connected drug delivery devices market.
Available
Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed
analysis and profiling of additional market players (up to five).
United States connected drug delivery devices market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]